Ahn Yeri, Hawkins Carolyn, Pearson Eliza, Kubler Paul
Canberra Hospital.
School of Medicine and Psychology, Australian National University, Canberra.
Aust Prescr. 2024 Dec;47(6):179-185. doi: 10.18773/austprescr.2024.055.
Antiphospholipid syndrome is an autoimmune disease characterised by thrombotic and/or obstetric manifestations with persistent antiphospholipid antibodies. Diagnosis involves confirming the persistence of antiphospholipid antibodies in symptomatic patients, using validated classification criteria as a guide. The likelihood of obtaining false-positive or false-negative test results in certain settings, and the lack of standardisation between laboratory methods, are important considerations. Patients who have had thrombotic manifestations require lifelong anticoagulation from the first thrombotic event, typically with warfarin. Patients with a history of thrombotic and/or obstetric manifestations who become pregnant should receive low-molecular-weight heparin and low-dose aspirin during pregnancy and postpartum. Testing asymptomatic people is not recommended, except in the context of systemic lupus erythematosus. Management of asymptomatic people with persistent antiphospholipid antibodies depends on their individual antibody profile and risk factors.
抗磷脂综合征是一种自身免疫性疾病,其特征为伴有持续抗磷脂抗体的血栓形成和/或产科表现。诊断包括在有症状的患者中确认抗磷脂抗体的持续存在,并以经过验证的分类标准为指导。在某些情况下获得假阳性或假阴性检测结果的可能性以及实验室方法之间缺乏标准化是重要的考虑因素。有血栓形成表现的患者从首次血栓形成事件起就需要终身抗凝,通常使用华法林。有血栓形成和/或产科表现病史且怀孕的患者在孕期和产后应接受低分子量肝素和小剂量阿司匹林治疗。除了在系统性红斑狼疮的背景下,不建议对无症状人群进行检测。对具有持续抗磷脂抗体的无症状人群的管理取决于其个体抗体谱和风险因素。